GlassScriptPhysician profile
Bridget Ehman
NPI 1386188365
$1,984.22
in general payments reported to CMS, 2019-2025
20 companies · $874 in 2025
The $874 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $391 · 2024: $720 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $398.10 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $261.26 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $251.15 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $198.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.92 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $125.61 | 2024-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $118.88 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.48 | 2023-2025 | Jardiance |
| Pfizer INC. | $65.24 | 2023-2025 | |
| Dexcom, INC. | $47.99 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $42.74 | 2025 | Korlym |
| Ibsa Pharma INC. | $30.89 | 2023-2025 | Tirosint, Licart, Licart |
| Boston Scientific Corporation | $30.17 | 2024 | |
| Idorsia Pharmaceuticals US INC | $29.90 | 2023 | Quviviq |
| Abbvie INC. | $27.04 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $26.58 | 2025 | Yupelri |
| Abbott Laboratories | $22.97 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $22.42 | 2025 | Airsupra |
| Inspire Medical Systems, INC. | $20.80 | 2025 | Inspire |
| Amneal Pharmaceuticals LLC | $17.77 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Ehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.